| Type of Material: | Thesis |
| Title: | Genetic variations in drug metabolizing genes and their clinical impact in lung cancer patients |
| Researcher: | Syed Subhani |
| Guide: | Kaiser Jamil | Avulappa S. |
| Department: | Faculty of Biotechnology |
| Publisher: | Jawaharlal Nehru Technological University, Hyderabad |
| Place: | Hyderabad |
| Year: | 2015 |
| Language: | English |
| Subject: | Biotechnology and Applied Microbiology | Genes | Life Sciences | Lung cancer | Microbiology | Biotechnology | Engineering and Technology |
| Dissertation/Thesis Note: | PhD; Faculty of Biotechnology, Jawaharlal Nehru Technological University, Hyderabad, Hyderabad; 2015 |
| Fulltext: | Shodhganga |
| 000 | 00000ntm a2200000ua 4500 | |
| 001 | 454273 | |
| 003 | IN-AhILN | |
| 005 | 2024-07-31 17:59:04 | |
| 008 | __ | 240731t2015||||ii#||||g|m||||||||||eng|| |
| 035 | __ | |a(IN-AhILN)th_454273 |
| 040 | __ | |aJNTU_500028|dIN-AhILN |
| 041 | __ | |aeng |
| 100 | __ | |aSyed Subhani|eResearcher |
| 110 | __ | |aFaculty of Biotechnology|bJawaharlal Nehru Technological University, Hyderabad|dHyderabad|ein|0U-0017 |
| 245 | __ | |aGenetic variations in drug metabolizing genes and their clinical impact in lung cancer patients |
| 260 | __ | |aHyderabad|bJawaharlal Nehru Technological University, Hyderabad|c2015 |
| 300 | __ | |a195p.|dDVD |
| 502 | __ | |cFaculty of Biotechnology, Jawaharlal Nehru Technological University, Hyderabad, Hyderabad|d2015|bPhD |
| 518 | __ | |dDecember 2015|oDate of Award |
| 518 | __ | |oDate of Registration|d2009-01-01 |
| 520 | __ | |aThis thesis investigates the genetic variations in drug metabolizing genes and their clinical impact in non-small cell lung cancers (NSCLC) patients. Lung cancers are usually adenocarcinomas that are most difficult to treat. The last decade has witnessed many advances in the diagnosis and treatment of lung cancer. Nevertheless, mortality still remains high as treatment strategies differ in different scenarios. The gold standard treatment mainly refers to the therapeutic regimens of antineoplastic drugs, or radiotherapy and surgery in a few instances. Several therapies are directed towards EGFR or Tyrosine Kinase Inhibitors (TKIs); however, for those patients who do not have mutations in either gene, the treatment is almost ineffective. In such situations more than 50% patients suffer due to drug resistance. It is now understood that mutations in drug metabolizing genes are responsible for the over-expression of their receptors in variousnewlinecancers. Hence, it is important to understanding the polymorphic |
| 650 | __ | |aBiotechnology|2UGC |
| 650 | __ | |aEngineering and Technology|2AIU |
| 653 | __ | |aBiotechnology and Applied Microbiology |
| 653 | __ | |aGenes |
| 653 | __ | |aLife Sciences |
| 653 | __ | |aLung cancer |
| 653 | __ | |aMicrobiology |
| 700 | __ | |aKaiser Jamil|eGuide |
| 700 | __ | |eCo-Guide|aAvulappa S. |
| 856 | __ | |uhttp://shodhganga.inflibnet.ac.in/handle/10603/292964|yShodhganga |
| 905 | __ | |afromsg |
User Feedback Comes Under This section.